Pfizer Inc. (NYSE: PFE) wouldn't give a discount to any developed country for its novel coronavirus (COVID-19) vaccine — over the price it's charging the United States under a contract signed last week — CEO Albert Bourla said at a conference call Tuesday.What Happened: "All the countries that are developed right now will not receive a lower price for the same volume commitment than the U.S.," Bourla said, as earlier reported by Reuters.The pharmaceutical company's pre-order deal with the U.S. government prices a single dose of the potential vaccine at $19.5, with the total course of two doses costing $39.Pfizer could change the prices once the coronavirus outbreak's official status as a pandemic is over, Reuters noted.The New York-based company began the late-stage clinical trials for its vaccine, co-developed with Germany's BioNTech SE (NASDAQ: BNTX), on Monday.Why It Matters: Rival Moderna Inc. (NASDAQ: MRNA) is looking to price its similar vaccine candidate in the range of $50 to $60, according to a report from the Financial Times the same day.Another vaccine candidate from AstraZeneca plc's (NYSE: AZN) appears to be priced around $3 to $4 per dose, under its agreements with the governments of the Netherlands, Germany, France, and Italy, according to an analyst note from SVB Leerink's Geoffrey Porges.Price Action: Pfizer shares closed about 4% higher at $39.02 on Tuesday, and were unchanged in the after-hours session.See more from Benzinga * Australia's University Of Queensland Starts COVID-19 Vaccine Clinical Trials * Early Coronavirus Vaccines Likely To Target Further Complications, Not Infection, Health Experts Say * Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
from Yahoo Finance https://ift.tt/2X6CYfr
Leave a Reply